PUMA BIOTECHNOLOGY INC

PUMA BIOTECHNOLOGY INC

Compare this stock

PBYI Stock Report Card

$

VolatilityTechnicalsSentimentProfitPerformanceEarningsAnalyst Price Targets

51%

Performance

Score:

100/100

PBYI returned 4.80% in the last 12 months. Based on SPY's performance of -21.18%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

83/100

9 analysts offer 12-month price targets for PBYI. Together, they have an average target of 0, the most optimistic target put PBYI at 0 within 12-months and the most pessimistic has PBYI at 0.

Sentiment

Score:

65/100

PBYI had a bullish sentiment score of 65.49% across Twitter and StockTwits over the last 12 months. It had an average of 5.77 posts, 2.74 comments, and 4.22 likes per day.

Technicals

Score:

36/100

PBYI receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

Score:

10/100

PBYI has missed earnings 6 times in the last 20 quarters.

Profit

Score:

34/100

Out of the last 20 quarters, PBYI has had 6 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

Score:

48/100

PBYI has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

PUMA BIOTECHNOLOGY INC Summary

Nasdaq / PBYI
Healthcare
Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.